Detalles de la búsqueda
1.
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.
Respir Res
; 23(1): 114, 2022 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35509077
2.
Staphylococcus aureus Skin and Soft Tissue Infection Recurrence Rates in Outpatients: A Retrospective Database Study at 3 US Medical Centers.
Clin Infect Dis
; 73(5): e1045-e1053, 2021 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197926
3.
Vaccines for Staphylococcus aureus and Target Populations.
Curr Top Microbiol Immunol
; 409: 491-528, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28197738
4.
Reverse development of vaccines against antimicrobial-resistant pathogens.
NPJ Vaccines
; 9(1): 71, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38570502
5.
The Impact of Educational Intervention on Willingness to Enroll in a Clinical Trial of a Gonorrhea Vaccine.
Vaccines (Basel)
; 11(3)2023 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36992233
6.
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
Vaccine
; 41(23): 3518-3524, 2023 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37142462
7.
Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial.
Hum Vaccin Immunother
; 19(1): 2187194, 2023 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36974988
8.
Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules.
Hum Vaccin Immunother
; 16(9): 2274-2279, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31951780
9.
Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10â¯years antibody persistence.
Vaccine
; 37(32): 4623-4629, 2019 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29397225
10.
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Hum Vaccin Immunother
; 14(1): 45-58, 2018 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29172945
11.
Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules.
Expert Rev Vaccines
; 16(9): 919-932, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28770638
12.
Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules".
Hum Vaccin Immunother
; 16(9): 2282-2284, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32810427
Resultados
1 -
12
de 12
1
Próxima >
>>